Patents Assigned to Vector Vitale IP LLC
  • Patent number: 12233089
    Abstract: Engineered food to promote health and maintain homeostasis in a subject and methods of producing the food.
    Type: Grant
    Filed: February 8, 2024
    Date of Patent: February 25, 2025
    Assignee: Vector Vitale IP LLC
    Inventors: Peter Y. Novak, Maxim Temnikov
  • Publication number: 20250032538
    Abstract: Disclosed are methods to restore homeostasis in a subject in need thereof; methods of treating or preventing a degenerative disease in a subject in need thereof; and methods of achieving anti-aging effect in a subject in need thereof. The disclosed methods establishes or rebuilds a homeostatic balance between electric and magnetic components of differential and integral characteristics of electromagnetic field in cells of said subject. The methods comprise administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising various essential chemical elements and additive chemical elements specific to each essential element.
    Type: Application
    Filed: October 14, 2024
    Publication date: January 30, 2025
    Applicant: Vector Vitale IP LLC
    Inventor: Peter NOVAK
  • Publication number: 20240398858
    Abstract: A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.
    Type: Application
    Filed: June 13, 2024
    Publication date: December 5, 2024
    Applicant: Vector Vitale IP LLC
    Inventors: Peter Y. Novak, Maxim V. Temnikov, Oleksandr Balakin
  • Patent number: 12138322
    Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.
    Type: Grant
    Filed: March 19, 2024
    Date of Patent: November 12, 2024
    Assignee: Vector Vitale IP LLC
    Inventors: Peter Novak, Max Temnik, Oleksandr Balakin
  • Publication number: 20240316098
    Abstract: A pharmaceutical composition is used for improving health, curing abnormalities and degenerative diseases, and achieving anti-aging therapeutic effect in mammals. The novel pharmaceutical composition includes a pharmaceutical carrier and an isotope selective component including at least one of a chemical element in which the isotopic ratio of at least one light isotope is altered to exceed natural abundance.
    Type: Application
    Filed: May 29, 2024
    Publication date: September 26, 2024
    Applicant: Vector Vitale IP LLC
    Inventors: Max Temnik, Sergey Gurin, Oleksandr Balakin, Peter Novak
  • Publication number: 20240316097
    Abstract: A pharmaceutical composition is used for improving health, curing abnormalities and degenerative diseases, and achieving anti-aging therapeutic effect in mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective component including at least one of a chemical element in which the isotopic ratio of at least one light isotope is altered to exceed natural abundance.
    Type: Application
    Filed: May 29, 2024
    Publication date: September 26, 2024
    Applicant: Vector Vitale IP LLC
    Inventors: Max Temnik, Sergey Gurin, Oleksandr Balakin, Peter Novak
  • Patent number: 12097215
    Abstract: An antibacterial composition that comprises as active compound at least one light isotope of an element selected from the group which consists of 1H, 12C, 16O, 14N, 39K, 24Mg, 64Zn, 85Rb, 28Si, 54Fe, 92Mo, 74Se, 58Ni, 70Ge, 52Cr, 63Cu, 50V, or combinations thereof, wherein the composition is enriched for the at least one light isotope. A method of treating and preventing bacterial diseases in humans and non-human animals by administering the composition. The use of the said composition in human and veterinary medicine for the prevention and treatment of diseases in humans and non-human animals and also as an antiseptic and disinfectant.
    Type: Grant
    Filed: January 23, 2023
    Date of Patent: September 24, 2024
    Assignee: Vector Vitale IP LLC
    Inventors: Peter Y. Novak, Maxim V. Temnikov, Oleksandr Balakin
  • Publication number: 20240285680
    Abstract: A method of treating or preventing Alzheimer's disease comprising administering a pharmaceutical composition comprising 64Zne or a salt thereof, at a therapeutically effective or a prophylactically effective dose for treating or preventing the disease.
    Type: Application
    Filed: February 20, 2024
    Publication date: August 29, 2024
    Applicant: Vector Vitale IP LLC
    Inventors: Peter Y. NOVAK, Maxim V. TEMNIKOV
  • Publication number: 20240261327
    Abstract: Engineered food to promote health and maintain homeostasis in a subject and methods of producing the food.
    Type: Application
    Filed: February 8, 2024
    Publication date: August 8, 2024
    Applicant: Vector Vitale IP LLC
    Inventors: Peter Y. NOVAK, Maxim TEMNIKOV
  • Patent number: 12036238
    Abstract: Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R1 through R14 is independently selected from H, OH, F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.
    Type: Grant
    Filed: August 28, 2023
    Date of Patent: July 16, 2024
    Assignee: Vector Vitale IP LLC
    Inventors: Peter Novak, Max Temnik, Oleksandr Balakin
  • Patent number: 12037309
    Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.
    Type: Grant
    Filed: November 1, 2023
    Date of Patent: July 16, 2024
    Assignee: Vector Vitale IP LLC
    Inventors: Peter Novak, Maxim Temnikov, Oleksandr Balakin
  • Publication number: 20240216552
    Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.
    Type: Application
    Filed: March 19, 2024
    Publication date: July 4, 2024
    Applicant: Vector Vitale IP LLC
    Inventors: Peter NOVAK, Max TEMNIK, Oleksandr BALAKIN
  • Patent number: 12011458
    Abstract: A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: June 18, 2024
    Assignee: Vector Vitale IP LLC
    Inventors: Peter Y. Novak, Maxim V. Temnikov, Oleksandr Balakin
  • Publication number: 20240173350
    Abstract: Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R1 through R14 is independently selected from H, OH, F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.
    Type: Application
    Filed: August 28, 2023
    Publication date: May 30, 2024
    Applicant: Vector Vitale IP LLC
    Inventors: Peter NOVAK, Max TEMNIK, Oleksandr BALAKIN
  • Patent number: 11986541
    Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.
    Type: Grant
    Filed: August 9, 2023
    Date of Patent: May 21, 2024
    Assignee: Vector Vitale IP LLC
    Inventors: Peter Novak, Max Temnik, Oleksandr Balakin
  • Publication number: 20240150280
    Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.
    Type: Application
    Filed: November 1, 2023
    Publication date: May 9, 2024
    Applicant: Vector Vitale IP LLC
    Inventors: Peter NOVAK, Maxim TEMNIKOV, Oleksandr BALAKIN
  • Patent number: 11896610
    Abstract: Engineered food to promote health and maintain homeostasis in a subject and methods of producing the food.
    Type: Grant
    Filed: July 21, 2022
    Date of Patent: February 13, 2024
    Assignee: Vector Vitale IP LLC
    Inventors: Peter Y. Novak, Maxim V. Temnikov
  • Publication number: 20230381347
    Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.
    Type: Application
    Filed: August 9, 2023
    Publication date: November 30, 2023
    Applicant: Vector Vitale IP LLC
    Inventors: Peter NOVAK, Max TEMNIK, Oleksandr BALAKIN
  • Patent number: 11827588
    Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: November 28, 2023
    Assignee: Vector Vitale IP LLC
    Inventors: Peter Novak, Maxim Temnikov, Oleksandr Balakin
  • Patent number: 11779597
    Abstract: Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R1 through R14 is independently selected from H, OH, F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: October 10, 2023
    Assignee: Vector Vitale IP LLC
    Inventors: Peter Novak, Maxim Temnikov, Oleksandr Balakin